Latest news with #NGM
Yahoo
6 hours ago
- Yahoo
Feds charge another Chinese citizen with smuggling biological materials for lab work
Another Chinese citizen is facing smuggling charges from the federal government, the third in a week, this time accused of bringing biological materials related to roundworms into the U.S. for her work at a University of Michigan laboratory. Chengxuan Han is charged with smuggling goods into the United States and making false statements, according to a criminal complaint in U.S. District Court in Detroit. She is to make an initial appearance June 9 in federal court. No attorney is listed for her in court records. Han is pursing a doctoral degree from the College of Life Science and Technology in the Huazhong University of Science and Technology in Wuhan, China, according to an affidavit filed with the complaint. From September 2024 to March, it indicated, she was listed as the sender of four packages of concealed or mis-manifested biological material addressed to two people associated with a lab at U-M. The affidavit did not name the lab or individuals, but it indicated the lab studies sensory biology, including mechanosensation, thermosensation, chemosensation, photosensation and nociception, and focuses on sensory transduction, sensory processing and sensory regulation of aging. The court filing indicated that Han's offer letter from U-M states she was invited as a visiting scholar to the lab. One recipient of the packages is listed an active member of the lab, and the other is listed as a member of the faculty and staff of the Life Sciences Institute at the university, according to the affidavit. More: Detention hearing adjourned for Chinese citizen accused in fungus smuggling case More: Feds: Chinese citizens charged with smuggling harmful fungus for research at U-M The packages did not contain the correct documentation and were not imported per correct U.S. Department of Agriculture or U.S. Customs and Border Protection regulations, according to the affidavit. Han arrived at Detroit Metro Airport from Shanghai on a J-1 visa June 8 and customs officers conducted an inspection and interview. She denied sending the packages to members of the lab, according to the affidavit, but when pressed, admitted to shipping them, with the materials from her research lab at the Chinese university. She initially told customs officers the packages were plastic cups, instead of petri dishes, the affidavit indicated, and a book "(omitting the envelope with suspected biological materials concealed in it.)" She then admitted sending packages containing "nematode growth medium 1 (NGM) (in the petri dishes) and plasmids (in the envelope)," according to the affidavit. In the filing, the FBI agent wrote that it was unlikely the petri dishes solely contained NGM, which is used to cultivate nematode worms in lab settings, because it is readily available and inexpensive in the U.S. Customs officials also found that she deleted the content of her electronic devices three days before arriving in the U.S., according to the affidavit. It indicates that she told authorities she deleted the content to "start fresh" while in the U.S. Eastern District of Michigan U.S. Attorney Jerome Gorgon, Jr. stated in a release that the alleged smuggling "is part of an alarming pattern that threatens our security. The American taxpayer should not be underwriting a (People's Republic of China)-based smuggling operation at one of our crucial public institutions." John Nowak, acting director of field operations for customs and border protection, added: "The guidelines for importing biological materials into the U.S. for research purposes are stringent, but clear, and actions like this undermine the legitimate work of other visiting scholars." Last week, Yunqing Jian, 33, and her boyfriend, Zunyong Liu, 34, were charged with conspiracy, smuggling goods into the United States, false statements and visa fraud in a separate case unsealed June 3. They are accused of smuggling a fungus that causes a disease in wheat, barley, maize and rice so that Liu could research the pathogen at a U-M lab where Jian works. Jian is being held pending a detention hearing June 13 in federal court. Liu is accused of smuggling the fungus into the country at the airport in clear plastic baggies in his backpack July 27. Customs officers denied him entry and processed him for expedited removal back to China, according to an affidavit in that case. Prosecutors indicated in a news release that the fungus is Fusarium graminearum, which scientific literature classifies as a potential agroterrorism weapon. It causes "head blight," a disease of the crops, and is responsible for billions of dollars in economic losses worldwide each year. The toxins the fungus produces can cause vomiting, liver damage and reproductive defects in livestock and humans, it indicated. The federal government also has charged a former U-M student from China, Haoxiang Gao, with voting illegally in the 2024 presidential election, then fleeing the country a day before President Donald Trump took office in January, according to the U.S. Attorney's Office. Contact Christina Hall: chall@ Follow her on X, formerly Twitter: @challreporter. Support local journalism. Subscribe to the Free Press. Submit a letter to the editor at This article originally appeared on Detroit Free Press: Feds charge another Chinese citizen with smuggling biological materials
Yahoo
4 days ago
- Business
- Yahoo
Global's Top Penny Stocks To Watch In June 2025
Global markets have been navigating a complex landscape, with U.S. stocks showing resilience amid trade policy uncertainties and inflation easing to its slowest pace in four years. Against this backdrop, investors might find opportunities in penny stocks—an investment area that, despite its somewhat outdated name, remains relevant for those seeking growth potential in smaller or newer companies. These stocks can offer surprising value when backed by strong financial health, presenting a mix of value and growth that larger firms might overlook. Name Share Price Market Cap Financial Health Rating EZZ Life Science Holdings (ASX:EZZ) A$1.50 A$71.94M ★★★★★★ Lever Style (SEHK:1346) HK$1.14 HK$725.59M ★★★★★★ Foresight Group Holdings (LSE:FSG) £3.96 £445.67M ★★★★★★ Angler Gaming (NGM:ANGL) SEK3.61 SEK270.7M ★★★★★★ CNMC Goldmine Holdings (Catalist:5TP) SGD0.44 SGD178.33M ★★★★★☆ Southern Cross Electrical Engineering (ASX:SXE) A$1.67 A$453.46M ★★★★★★ Tasmea (ASX:TEA) A$3.08 A$716.16M ★★★★★☆ Yangzijiang Shipbuilding (Holdings) (SGX:BS6) SGD2.31 SGD9.09B ★★★★★☆ Bosideng International Holdings (SEHK:3998) HK$4.39 HK$50.15B ★★★★★★ Croma Security Solutions Group (AIM:CSSG) £0.86 £11.84M ★★★★★★ Click here to see the full list of 5,587 stocks from our Global Penny Stocks screener. We'll examine a selection from our screener results. Simply Wall St Financial Health Rating: ★★★★★☆ Overview: Shenzhen Asia Link Technology Development Co., Ltd. operates in the technology sector with a market capitalization of CN¥1.66 billion. Operations: No specific revenue segments have been reported for this company. Market Cap: CN¥1.66B Shenzhen Asia Link Technology Development Co., Ltd. is navigating the penny stock landscape with a market cap of CN¥1.66 billion, demonstrating resilience through its substantial cash runway exceeding three years at current free cash flow levels. Despite being unprofitable with negative return on equity, it has reduced losses by 24.7% annually over five years and boasts a seasoned management team and board of directors. Recent earnings reveal improved financial performance, with Q1 2025 revenues rising to CN¥104.95 million from CN¥83.29 million year-over-year, indicating potential growth amidst existing short-term liabilities challenges and stable debt levels relative to assets. Unlock comprehensive insights into our analysis of Shenzhen Asia Link Technology DevelopmentLtd stock in this financial health report. Gain insights into Shenzhen Asia Link Technology DevelopmentLtd's past trends and performance with our report on the company's historical track record. Simply Wall St Financial Health Rating: ★★★★☆☆ Overview: Guizhou Bailing Group Pharmaceutical Co., Ltd. operates in the pharmaceutical industry, focusing on the development, production, and sale of traditional Chinese medicine products, with a market cap of CN¥5.65 billion. Operations: No specific revenue segments have been reported for the company. Market Cap: CN¥5.65B Guizhou Bailing Group Pharmaceutical Co., Ltd. is navigating financial challenges with a market cap of CN¥5.65 billion, having recently turned profitable despite a significant earnings decline over five years. The company reported Q1 2025 revenues of CN¥760.59 million, down from the previous year, and net income of CN¥24.17 million. Its debt management shows improvement with a reduced debt-to-equity ratio and satisfactory net debt levels supported by operating cash flow covering 23% of its debt. However, short-term liabilities match short-term assets, posing liquidity concerns amidst stable weekly volatility and experienced management oversight. Jump into the full analysis health report here for a deeper understanding of Guizhou Bailing Group Pharmaceutical. Examine Guizhou Bailing Group Pharmaceutical's past performance report to understand how it has performed in prior years. Simply Wall St Financial Health Rating: ★★★★☆☆ Overview: Hainan RuiZe New Building Material Co., Ltd operates in China, focusing on the production and sale of commercial concrete and municipal sanitation services, with a market cap of CN¥3.98 billion. Operations: The company generates revenue primarily from its operations in China, amounting to CN¥1.23 billion. Market Cap: CN¥3.98B Hainan RuiZe New Building Material Co., Ltd, with a market cap of CN¥3.98 billion, faces financial challenges as it remains unprofitable with increasing losses over the past five years. Despite reporting sales of CN¥1.28 billion for 2024, revenue declined from the previous year, and net losses persisted at CN¥241.53 million. The company's high net debt to equity ratio of 175.8% raises concerns about its financial leverage, although it maintains a stable cash runway due to positive free cash flow growth. Additionally, short-term assets exceed both short and long-term liabilities, providing some balance sheet strength amidst volatility stability. Navigate through the intricacies of Hainan RuiZe New Building MaterialLtd with our comprehensive balance sheet health report here. Learn about Hainan RuiZe New Building MaterialLtd's historical performance here. Take a closer look at our Global Penny Stocks list of 5,587 companies by clicking here. Contemplating Other Strategies? Explore 22 top quantum computing companies leading the revolution in next-gen technology and shaping the future with breakthroughs in quantum algorithms, superconducting qubits, and cutting-edge research. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Companies discussed in this article include SZSE:002316 SZSE:002424 and SZSE:002596. This article was originally published by Simply Wall St. Have feedback on this article? Concerned about the content? with us directly. Alternatively, email editorial-team@ Sign in to access your portfolio
Yahoo
5 days ago
- Business
- Yahoo
3 Global Penny Stocks With Market Caps Over US$400M To Watch
Global markets have been navigating a complex landscape, with U.S. stocks closing higher amid ongoing trade policy discussions and easing inflation rates. In this context, investors are increasingly looking for opportunities that balance affordability with potential growth. Penny stocks, though often seen as a relic of the past, continue to offer intriguing prospects; these typically smaller or newer companies can provide significant upside when backed by strong financials. Name Share Price Market Cap Financial Health Rating EZZ Life Science Holdings (ASX:EZZ) A$1.525 A$71.7M ★★★★★★ Lever Style (SEHK:1346) HK$1.15 HK$725.59M ★★★★★★ Foresight Group Holdings (LSE:FSG) £4.02 £452.42M ★★★★★★ Angler Gaming (NGM:ANGL) SEK3.70 SEK277.44M ★★★★★★ CNMC Goldmine Holdings (Catalist:5TP) SGD0.445 SGD180.35M ★★★★★☆ Tasmea (ASX:TEA) A$3.06 A$732.54M ★★★★★☆ Yangzijiang Shipbuilding (Holdings) (SGX:BS6) SGD2.21 SGD8.7B ★★★★★☆ LSL Property Services (LSE:LSL) £2.81 £290.33M ★★★★★☆ Bosideng International Holdings (SEHK:3998) HK$4.38 HK$50.26B ★★★★★★ Croma Security Solutions Group (AIM:CSSG) £0.86 £11.84M ★★★★★★ Click here to see the full list of 5,595 stocks from our Global Penny Stocks screener. We're going to check out a few of the best picks from our screener tool. Simply Wall St Financial Health Rating: ★★★★★★ Overview: STI Education Systems Holdings, Inc., with a market cap of ₱14.24 billion, operates through its subsidiaries to offer a variety of educational services in the Philippines. Operations: The company generates revenue of ₱5.49 billion from its educational services, including schools, colleges, and universities in the Philippines. Market Cap: ₱14.24B STI Education Systems Holdings, Inc. demonstrates a stable financial position with revenue of ₱5.49 billion and net income growth to ₱1,600.84 million for the recent nine months. The company's earnings have grown by 49.2% over the past year, surpassing industry averages, although this is below its five-year average growth rate of 62.7%. Its net debt to equity ratio of 0.7% is satisfactory, and short-term assets exceed liabilities significantly. Despite a low return on equity at 17.7%, STI offers high-quality earnings and reliable dividends at 2.68%, trading well below estimated fair value with experienced management in place. Click to explore a detailed breakdown of our findings in STI Education Systems Holdings' financial health report. Gain insights into STI Education Systems Holdings' historical outcomes by reviewing our past performance report. Simply Wall St Financial Health Rating: ★★★★★☆ Overview: Sinopec Shanghai Petrochemical Company Limited, along with its subsidiaries, engages in the manufacturing and sale of petroleum and chemical products in China, with a market capitalization of approximately HK$26.49 billion. Operations: No specific revenue segments are reported for the company. Market Cap: HK$26.49B Sinopec Shanghai Petrochemical Company Limited has shown resilience despite challenges, with recent strategic moves like the Steam Sales Contract with Baling New Materials potentially enhancing resource utilization and reducing costs. The company has become profitable in the past year, although its return on equity remains low at 0.6%. While earnings have declined over five years, they are forecast to grow significantly. The company's financial stability is supported by short-term assets exceeding liabilities and a strong cash position relative to debt, bolstered by a substantial share buyback program that reflects confidence in its valuation and future prospects. Dive into the specifics of Sinopec Shanghai Petrochemical here with our thorough balance sheet health report. Learn about Sinopec Shanghai Petrochemical's future growth trajectory here. Simply Wall St Financial Health Rating: ★★★★☆☆ Overview: Infund Holding Co., Ltd. operates in China, focusing on the production of micro enameled wire and veterinary vaccines, with a market cap of CN¥3.47 billion. Operations: Infund Holding Co., Ltd. has not reported any specific revenue segments. Market Cap: CN¥3.47B Infund Holding Co., Ltd. has shown significant revenue growth, reporting CN¥294.68 million for Q1 2025 compared to CN¥16.65 million a year ago, transitioning from a net loss to a net income of CN¥14.21 million. Despite being unprofitable in the past, the company has reduced its losses over five years by 26.2% annually and improved its debt-to-equity ratio from 11.3% to 1.9%. Short-term assets exceed liabilities, providing some financial stability; however, with less than a year of cash runway and negative return on equity (-12.88%), financial challenges persist amidst stable weekly volatility (8%). Click here and access our complete financial health analysis report to understand the dynamics of Infund Holding. Understand Infund Holding's track record by examining our performance history report. Investigate our full lineup of 5,595 Global Penny Stocks right here. Seeking Other Investments? Rare earth metals are an input to most high-tech devices, military and defence systems and electric vehicles. The global race is on to secure supply of these critical minerals. Beat the pack to uncover the 24 best rare earth metal stocks of the very few that mine this essential strategic resource. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Companies discussed in this article include PSE:STI SEHK:338 and SZSE:002141. This article was originally published by Simply Wall St. Have feedback on this article? Concerned about the content? with us directly. Alternatively, email editorial-team@ Sign in to access your portfolio
Yahoo
08-05-2025
- Business
- Yahoo
European Penny Stocks To Consider In May 2025
As European markets show resilience with the pan-European STOXX Europe 600 Index rising by 3.44% amidst easing tariff concerns, investors are increasingly exploring diverse opportunities across the continent. Penny stocks, a term that may seem outdated, continue to capture interest due to their potential for significant value and growth within smaller or less-established companies. By focusing on financial strength and clear growth prospects, these stocks can offer investors a chance to uncover promising opportunities in Europe's evolving market landscape. Top 10 Penny Stocks In Europe Name Share Price Market Cap Financial Health Rating Transferator (NGM:TRAN A) SEK2.66 SEK263.68M ★★★★★☆ Angler Gaming (NGM:ANGL) SEK3.75 SEK281.19M ★★★★★★ Hifab Group (OM:HIFA B) SEK3.48 SEK211.72M ★★★★★★ IMS (WSE:IMS) PLN3.66 PLN124.05M ★★★★☆☆ AMSC (OB:AMSC) NOK1.538 NOK110.53M ★★★★★★ Cellularline (BIT:CELL) €2.58 €54.42M ★★★★★☆ Netgem (ENXTPA:ALNTG) €0.995 €33.32M ★★★★★★ Fondia Oyj (HLSE:FONDIA) €4.67 €17.46M ★★★★★★ Mistral Iberia Real Estate SOCIMI (BME:YMIB) €1.01 €22.01M ★★★★★☆ Deceuninck (ENXTBR:DECB) €2.13 €294.08M ★★★★★★ Click here to see the full list of 433 stocks from our European Penny Stocks screener. Let's take a closer look at a couple of our picks from the screened companies. Simply Wall St Financial Health Rating: ★★★★☆☆ Overview: Valbiotis SA focuses on the research and development of dietary supplements aimed at preventing metabolic and cardiovascular diseases in France, with a market cap of €17.88 million. Operations: The company generates revenue from its Vitamins & Nutrition Products segment, amounting to €0.18 million. Market Cap: €17.88M Valbiotis SA, a pre-revenue biotech company with a market cap of €17.88 million, focuses on dietary supplements for metabolic and cardiovascular disease prevention. Despite having more cash than its total debt and seasoned management, the company faces financial challenges with less than a year of cash runway based on current free cash flow. Recent earnings showed a significant decrease in sales to €0.18 million from the previous year's €4.73 million, alongside an increased net loss of €10.03 million. While trading at 78.6% below estimated fair value, profitability remains elusive over the next three years according to forecasts. ENXTPA:ALVAL Debt to Equity History and Analysis as at May 2025 Simply Wall St Financial Health Rating: ★★★★☆☆ Overview: Alpcot Holding AB (publ) operates a digital platform for personal finance in the financial industry in Sweden, with a market cap of approximately SEK144.57 million.
Yahoo
04-04-2025
- Business
- Yahoo
Global Penny Stocks To Watch In April 2025
As global markets grapple with economic uncertainty and inflation fears, investors are increasingly cautious about their next moves. Despite these challenges, penny stocks continue to offer intriguing opportunities for those interested in smaller or newer companies that may provide growth potential at lower price points. By focusing on financial strength and solid fundamentals, investors can identify penny stocks that stand out as hidden gems with the potential for rewarding outcomes. Name Share Price Market Cap Financial Health Rating CNMC Goldmine Holdings (Catalist:5TP) SGD0.385 SGD156.04M ★★★★★☆ Angler Gaming (NGM:ANGL) SEK3.55 SEK266.2M ★★★★★★ NEXG Berhad (KLSE:DSONIC) MYR0.25 MYR695.54M ★★★★★★ DXN Holdings Bhd (KLSE:DXN) MYR0.50 MYR2.49B ★★★★★★ Lever Style (SEHK:1346) HK$1.29 HK$813.93M ★★★★★★ Next 15 Group (AIM:NFG) £2.62 £260.57M ★★★★☆☆ Warpaint London (AIM:W7L) £3.825 £309.01M ★★★★★★ Foresight Group Holdings (LSE:FSG) £3.365 £381.26M ★★★★★★ QinetiQ Group (LSE:QQ.) £3.926 £2.17B ★★★★★☆ EZZ Life Science Holdings (ASX:EZZ) A$1.46 A$69.82M ★★★★★★ Click here to see the full list of 5,585 stocks from our Global Penny Stocks screener. Let's take a closer look at a couple of our picks from the screened companies. Simply Wall St Financial Health Rating: ★★★★☆☆ Overview: Yunkang Group Limited is a medical operation service provider in the People's Republic of China with a market cap of HK$1.87 billion. Operations: The company generates revenue from its Diagnostic Services segment, totaling CN¥711.88 million. Market Cap: HK$1.87B Yunkang Group Limited, with a market cap of HK$1.87 billion, faces challenges typical of many penny stocks. Despite generating CN¥711.88 million in revenue from its Diagnostic Services segment, the company reported a significant net loss of CN¥791.68 million for 2024, up from the previous year. Its board is relatively new with an average tenure of 2.9 years, and while it has more cash than debt and positive operating cash flow covering its debt well (24%), its share price remains highly volatile and trades at 55.4% below estimated fair value amidst intensified industry competition and strategic restructuring efforts. Unlock comprehensive insights into our analysis of Yunkang Group stock in this financial health report. Understand Yunkang Group's earnings outlook by examining our growth report. Simply Wall St Financial Health Rating: ★★★★★★ Overview: Daisho Microline Holdings Limited is an investment holding company involved in the manufacture and trading of printed circuit boards across Hong Kong, Europe, the People's Republic of China, South Korea, North America, and other international markets with a market cap of HK$262.97 million. Operations: The company's revenue is derived from the manufacturing and trading of printed circuit boards, generating HK$28.84 million, and printing and packaging products, contributing HK$56.87 million. Market Cap: HK$262.97M Daisho Microline Holdings Limited, with a market cap of HK$262.97 million, is unprofitable but has reduced its losses over the past five years and maintains a debt-free status. The company generates revenue from printed circuit boards (HK$28.84 million) and printing products (HK$56.87 million). Despite high weekly volatility, Daisho Microline's short-term assets exceed both its short and long-term liabilities, providing financial stability. Recent auditor changes saw Prism Hong Kong Limited replace Forvis Mazars after a disagreement on audit fees; however, this transition is not expected to impact the company's annual audit or results release significantly. Jump into the full analysis health report here for a deeper understanding of Daisho Microline Holdings. Evaluate Daisho Microline Holdings' historical performance by accessing our past performance report. Simply Wall St Financial Health Rating: ★★★★★★ Overview: Guangdong Jialong Food Co., Ltd. engages in the research, development, production, and sale of food products in China with a market cap of CN¥2.27 billion. Operations: The company's revenue primarily comes from its operations in China, amounting to CN¥241.98 million. Market Cap: CN¥2.27B Guangdong Jialong Food, with a market cap of CN¥2.27 billion, is unprofitable and has seen its losses increase by 55.5% annually over the past five years. Despite this, the company remains debt-free and its short-term assets of CN¥393.2 million comfortably cover both short-term (CN¥44.4 million) and long-term liabilities (CN¥17.5 million). The board of directors is seasoned with an average tenure of 14.6 years, while shareholders have not faced significant dilution recently. However, earnings growth remains elusive as revenue primarily from China totals CN¥241.98 million without substantial improvement in profitability indicators. Click here and access our complete financial health analysis report to understand the dynamics of Guangdong Jialong Food. Gain insights into Guangdong Jialong Food's historical outcomes by reviewing our past performance report. Navigate through the entire inventory of 5,585 Global Penny Stocks here. Ready To Venture Into Other Investment Styles? The latest GPUs need a type of rare earth metal called Neodymium and there are only 20 companies in the world exploring or producing it. Find the list for free. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Companies discussed in this article include SEHK:2325 SEHK:567 and SZSE:002495. Have feedback on this article? Concerned about the content? with us directly. Alternatively, email editorial-team@ Sign in to access your portfolio
